Squamous cell carcinoma of esophagus
|
0.700 |
Biomarker
|
disease |
BEFREE |
In conclusion, our study first reported that PTP1B was the positive regulator of EGFR by dephosphorylating MYH9 at Y1408 to promote cell migration and invasion, which revealed the regulatory mechanism of PTP1B-MYH9-EGFR axis in ESCC.
|
31735331 |
2020 |
Squamous cell carcinoma of esophagus
|
0.700 |
Biomarker
|
disease |
BEFREE |
Single Nucleotide Polymorphisms in MicroRNA-Binding Site of Epidermal Growth Factor Receptor Signaling Pathway and Susceptibility to Esophageal Squamous Cell Carcinoma.
|
31269493 |
2020 |
Squamous cell carcinoma of esophagus
|
0.700 |
Biomarker
|
disease |
BEFREE |
The effect of anti-epidermal growth factor receptor targeted treatment in esophageal squamous cell carcinoma (ESCC) is still unclear.
|
31031851 |
2019 |
Squamous cell carcinoma of esophagus
|
0.700 |
Biomarker
|
disease |
BEFREE |
However, the specific effects of miR-133b and EGFR on ESCC remain unclear.
|
30594787 |
2019 |
Squamous cell carcinoma of esophagus
|
0.700 |
Biomarker
|
disease |
BEFREE |
<i>Conclusion:</i> Our results establish the functional role of RNF128 in driving the invasion and metastasis of ESCC through the EGFR/MAPK/MMP-2 pathway, implicating its potential as a candidate therapeutic target and prognostic biomarker for ESCC.
|
31216681 |
2019 |
Squamous cell carcinoma of esophagus
|
0.700 |
Biomarker
|
disease |
BEFREE |
LR004-VC-MMAE showed a potent antitumor effect against ESCC and other EGFR-positive cells with IC<sub>50</sub> values of nM concentrations in vitro.
|
30372581 |
2019 |
Squamous cell carcinoma of esophagus
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The results showed that CC genotype of both PLCE1 rs17109671 and EGFR rs2072454 was associated with ESCC prognosis.
|
31209807 |
2019 |
Squamous cell carcinoma of esophagus
|
0.700 |
Biomarker
|
disease |
BEFREE |
ITGB4/FAK/growth factor receptor-bound protein 2 (Grb2), protein kinase B (AKT), and extracellular signal-regulated kinase (ERK) pathways were involved in the regulatory mechanisms of miR-133b/EGFR axis in ESCC metastases in vitro and in vivo.
|
30479571 |
2018 |
Squamous cell carcinoma of esophagus
|
0.700 |
Biomarker
|
disease |
BEFREE |
Overall, our results suggest that an ESCC subtype with EGFR amplification and overexpression benefits from cetuximab treatment, which warrants further clinical confirmation.
|
30416780 |
2018 |
Squamous cell carcinoma of esophagus
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
EGFR family protein expression was examined by immunohistochemical analysis of tissue microarrays of 94 patients with lymph node-negative ESCC after radical esophagectomy with three-field lymphadenectomy.
|
29729836 |
2018 |
Squamous cell carcinoma of esophagus
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The present study investigated the role of miR-1 and its association with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α (PIK3CA) in the pathophysiology of esophageal squamous cell carcinoma (ESCC), and analyzed the effects of miR-1 inhibitor or mimics on sensitivity to epidermal growth factor receptor-tyrosine kinase inhibitors, the alterations of cell cycle distribution and apoptosis in ESCC cells.
|
29399158 |
2018 |
Squamous cell carcinoma of esophagus
|
0.700 |
Biomarker
|
disease |
BEFREE |
Specifically, EGFR and p120-catenin (p120ctn) are commonly dysregulated genes that are indicative of poor prognosis in ESCC.
|
29541406 |
2018 |
Squamous cell carcinoma of esophagus
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
These data suggests SIRT1 may serve as a predictor of poor prognosis in ESCC, and its mediated tumor-promoting role might be associated with the overexpression of EGFR protein in ESCC.
|
29625788 |
2018 |
Squamous cell carcinoma of esophagus
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Taken together, the current study was the first to demonstrate the upregulation of PD-L1 by chemotherapy in ESCC and its regulation through the EGFR/ERK pathway.
|
30172884 |
2018 |
Squamous cell carcinoma of esophagus
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
This study confirms a direct correlation between MSI1 and EGFR and may support the important role of MSI1 in activation of EGFR through NOTCH/WNT pathways in ESCC.
|
30202417 |
2018 |
Squamous cell carcinoma of esophagus
|
0.700 |
Biomarker
|
disease |
BEFREE |
Both ESCC cell lines and PDXs with EGFR CNG or overexpression are potential candidates for afatinib, and concomitant EGFR/SFKs inhibition could reverse afatinib-acquired resistance caused by SFKs activation in ESCC.
|
30157900 |
2018 |
Squamous cell carcinoma of esophagus
|
0.700 |
Biomarker
|
disease |
BEFREE |
In conclusion, PET imaging biomarkers may be useful for selecting patients that express target molecules and for monitoring therapeutic efficacy of EGFR-targeted therapy in ESCC patients.
|
30373221 |
2018 |
Squamous cell carcinoma of esophagus
|
0.700 |
Biomarker
|
disease |
BEFREE |
CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma.
|
28059068 |
2017 |
Squamous cell carcinoma of esophagus
|
0.700 |
Biomarker
|
disease |
BEFREE |
We identified 11 emerging IHC markers with reproducible results, including eight markers [epidermal growth factor receptor (EGFR), Cyclin D1, vascular endothelial growth factor (VEGF), Survivin, Podoplanin, Fascin, phosphorylated mammalian target of rapamycin (p-mTOR), and pyruvate kinase M2 (PKM2)] indicating unfavorable prognosis and 3 markers (P27, P16, and E-cadherin) indicating favorable prognosis of ESCC.
|
28818096 |
2017 |
Squamous cell carcinoma of esophagus
|
0.700 |
Biomarker
|
disease |
BEFREE |
The pre-treatment of ESCC cell strains was carried out using Butaprost (special agonist of PGE2 and EP2) and RNAi of EP2, and we observed the expression of EP2, EGFR, and p-EGFR.
|
29272001 |
2017 |
Squamous cell carcinoma of esophagus
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In ESCC cell lines with EGFR high expression, PD-L1 expression was induced significantly when EGFR signaling was activated by radiation and was dramatically inhibited by an EGFR tyrosine kinase inhibitor.
|
28192623 |
2017 |
Squamous cell carcinoma of esophagus
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
It has been reported that <sup>64</sup> Cu-cetuximab immune-PET represented EGFR expression levels in ESCC tumors and that <sup>177</sup> Lu-cetuximab radioimmunotherapy effectively inhibited the tumor growth.
|
28777832 |
2017 |
Squamous cell carcinoma of esophagus
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Functional studies demonstrate that PCLO knockdown remarkably attenuates ESCC malignancy in vitro and in vivo, and ectopic EGFR expression partially compensates for Piccolo loss.
|
28263981 |
2017 |
Squamous cell carcinoma of esophagus
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The western blotting results showed that exposure of ESCC cells to resveratrol inhibited EGF-induced EGFR activation in addition to decreasing the total protein levels of EGFR and membrane/nuclear localization.
|
28123566 |
2017 |
Squamous cell carcinoma of esophagus
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In this retrospective study, we assessed EGFR overexpression, using immunohistochemistry (IHC) in 68 patients with ESCC, undergoing neoadjuvant chemoradiotherapy and esophagectomy in 2011-2014.
|
28412829 |
2017 |